What is ABCL's current stock price?

ABCL (AbCellera Biologics Inc.) is currently trading at $5.20 with a market cap of $1.59B.

What sector is AbCellera Biologics Inc. in?

AbCellera Biologics Inc. (ABCL) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is ABCL a good stock to buy?

Analysts have a Buy consensus on ABCL with a price target of $7.50. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

ABCL AbCellera Biologics Inc.

Healthcare

$5.20+1.17%ClosedMarket Cap: $1.59B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

1.68

P/S

20.05

EV/EBITDA

-9.45

DCF Value

$-1.92

FCF Yield

-11.9%

Div Yield

0.0%

Margins & Returns

Gross Margin

79.1%

Operating Margin

-267.6%

Net Margin

-181.7%

ROE

-14.2%

ROA

-11.0%

ROIC

-13.8%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$8.3M	$-43.2M	$—
Q4 null	$44.9M	$-8.9M	$—
FY null	$75.1M	$-146.4M	$—
Q3 null	$9.0M	$-57.1M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$7.50

Target (Median)

$7.50

Target Range

$7.00 - $8.00

1 Strong Buy7 Buy1 Hold0 Sell0 Strong Sell

Leerink PartnersMarket Perform

2025-11-07

StifelBuy

2025-08-08

KeybancOverweight

2025-07-14

Trading Activity

Insider Trades

View All

Montalbano John S.director

BuyMon May 18

Thermopylae Holdings Ltd.10 percent owner

BuyMon Mar 02

Thermopylae Holdings Ltd.10 percent owner

BuyFri Feb 27

Booth Andrewofficer: Chief Financial Officer

BuyFri Feb 27

Stimart Trynofficer: Chief Legal Officer

SellMon Jan 05

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.03

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Peers